Medically reviewed on November 13, 2017.
Applies to the following strengths: 500 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Skin and Structure Infection
1000 mg IV, followed one week later by 500 mg IV
Comments: Infuse over 30 minutes.
Uses: Treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus).
Renal Dose Adjustments
Mild to moderate renal impairment (CrCl 30 to 79 mL/min): No adjustment recommended
Severe renal impairment (CrCl less than 30 mL/min): 750 mg IV, followed one week later by 375 mg IV.
Liver Dose Adjustments
Mild hepatic impairment (Child-Pugh Class A): No adjustment recommended
Moderate to severe hepatic impairment (Child-Pugh Class B or C): Data not available; use with caution
Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
Hemodialysis: No adjustment recommended. Dalbavancin can be administered without regard to the timing of hemodialysis.
Peritoneal dialysis: Data not available
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
-Do not co-infuse with other medications or electrolytes.
-Saline-based infusion solutions may cause precipitation and should not be used.
-If the IV line is used to administer other drugs, flush the line with 5% Dextrose injection before and after each dalbavancin infusion.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about dalbavancin
- Dalbavancin Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: glycopeptide antibiotics
Other brands: Dalvance